GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 3,661 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,661 shares of GeneDx stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $76.37, for a total value of $279,590.57. Following the completion of the sale, the chief executive officer now directly owns 62,897 shares in the company, valued at approximately $4,803,443.89. This represents a 5.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $143,456.40.

GeneDx Trading Down 2.8 %

GeneDx stock opened at $71.77 on Friday. The stock has a 50-day simple moving average of $69.70 and a 200 day simple moving average of $44.98. The stock has a market capitalization of $1.97 billion, a P/E ratio of -23.08 and a beta of 2.04. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a 52 week low of $1.66 and a 52 week high of $89.11.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The company had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. During the same period in the previous year, the company posted ($0.82) EPS. The firm’s revenue for the quarter was up 44.3% compared to the same quarter last year. Analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of GeneDx by 4.2% during the first quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock worth $6,460,000 after buying an additional 28,678 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of GeneDx during the 2nd quarter worth approximately $9,575,000. Calamos Advisors LLC bought a new position in shares of GeneDx during the second quarter worth approximately $1,137,000. Bank of New York Mellon Corp acquired a new stake in shares of GeneDx in the second quarter valued at approximately $991,000. Finally, nVerses Capital LLC acquired a new stake in GeneDx during the second quarter worth approximately $50,000. 61.72% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

WGS has been the subject of a number of recent research reports. Craig Hallum increased their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Wells Fargo & Company increased their price target on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Finally, The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.